ORIGINAL CONTRIBUTION

Association of Long-Distance Corridor Walk Performance With Mortality, Cardiovascular Disease, Mobility Limitation, and Disability
Anne B. Newman, MD, MPH Eleanor M. Simonsick, PhD Barbara L. Naydeck, MPH Robert M. Boudreau, PhD Stephen B. Kritchevsky, PhD Michael C. Nevitt, PhD Marco Pahor, MD Suzanne Satterfield, MD, DrPH Jennifer S. Brach, PhD, PT, GCS Stephanie A. Studenski, MD, MPH Tamara B. Harris, MD, MS
Context Aerobic fitness, an important predictor of cardiovascular disease and mortality, is difficult to assess by maximal exercise testing in older adults. Extended walking tests have been examined as outcome predictors in medically ill populations but not in community-dwelling older adults. Objective To determine whether an extended walking test predicts poor outcomes in older adults. Design, Setting, and Participants Observational cohort study enrolling 3075 community-dwelling adults aged 70 to 79 years living in Pittsburgh, Pa, or Memphis, Tenn. Of those participating in the Health, Aging, and Body Composition Study, 1584 (52%) were women and 1281 (42%) were black. Participants enrolled from March 1997 to April 1998. Ability to complete the long-distance corridor walk and total performance time was assessed at the baseline examination. Main Outcome Measures Total mortality, incident cardiovascular disease, incident mobility limitation, and mobility disability were ascertained after a mean (SD) of 4.9 (0.9) years. Results Among patients eligible to exercise, 351 died, 308 had episodes of incident cardiovascular disease, 1116 had occurrences of mobility limitation, and 509 had occurrences of mobility disability. Inability to complete walking 400 m tended to be associated with a higher risk of mortality and incident cardiovascular disease and, after accounting for potential confounders, was associated with incident mobility limitation (212.6 vs 79.1 events/1000 person-years; adjusted hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.58-2.18; P.001) and mobility disability (85.2 vs 28.8 events/1000 person-years; adjusted HR, 1.95; 95% CI, 1.56-2.44; P.001). Of those who completed 400 m, each additional minute of performance time was associated with an adjusted HR of 1.29 (95% CI, 1.121.48) for mortality, 1.20 (95% CI, 1.01-1.42) for incident cardiovascular disease, 1.52 (95% CI, 1.41-1.63) for mobility limitation, and 1.52 (95% CI, 1.37-1.70) for disability after adjustment for demographics, health behaviors, clinical and subclinical disease, and cardiovascular disease risk factors. Findings were consistent in both men and women and blacks and whites. Among participants who completed the test and after adjusting for potential confounders, those in the poorest quartile of functional capacity (walk time 362 seconds) had a higher risk of death than those in the best quartile (walk time 290 seconds; adjusted HR, 3.23; 95% CI, 2.11-4.94; P.001). Conclusions Older adults in the community who reported no difficulty walking had a wide range of performance on this extended walking test. Ability to do the test and performance were important prognostic factors for total mortality, cardiovascular disease, mobility limitation, and mobility disability in persons in their eighth decade.
JAMA. 2006;295:2018-2026 Author Affiliations are listed at the end of this article. Corresponding Author: Anne B. Newman, MD, MPH, www.jama.com 130 N Bellefield St, Room 532, University of Pittsburgh, Pittsburgh, PA 15213 (newmana@edc.pitt .edu).

and cardiovascular response to exercise, especially heart rate recovery,5-8 have been shown in middle-aged adults to predict cardiovascular and total mortality. Extended walking tests have been used to assess exercise capacity in medically ill populations.9-12 The long-distance corridor walk is similar to the 6-minute walk test,13 which has been shown to predict mortality in patients with congestive heart failure.14 Both the 6-minute and the longdistance corridor walk test are associated with several long-term health conditions and measures of subclinical disease including cardiovascular, musculoskeletal, and neurological conditions.15,16 Performance on extended walking tests of varying times and distances have been shown to be strongly related to directly measured oxygen consumption.17-19 Potentially, such tests
2018

XERCISE CAPACITY OR FITNESS1-4

JAMA, May 3, 2006Vol 295, No. 17 (Reprinted with Corrections)

2006 American Medical Association. All rights reserved.

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

could discriminate risk for future adverse health events in those with no overt evidence of poor health and who appear to be well functioning. We hypothesized that the ability to complete the 400-m walk component of the longdistance corridor walk, the performance time, and the cardiovascular response to this task would predict mortality, cardiovascular disease, mobility limitation, and disability in a cohort of well-functioning older adults. METHODS
Population

Long-Distance Corridor Walk

The Health, Aging, and Body Composition (Health ABC) study was designed to assess the relationship between body composition, long-term conditions, and incident mobility limitation in an initially well-functioning older adult cohort. From March 1997 to April 1998, the study enrolled 3075 people aged 70 to 79 years, of whom 1584 (52%) were women and 1281 (42%) were black. Potential participants were recruited from a random sample of white and all black Medicare beneficiaries residing in designated ZIP code areas in Pittsburgh, Pa, and Memphis, Tenn, with a mailed invitation followed by a telephone screening interview to determine eligibility. Race was defined by self-report. Eligible participants reported no difficulty walking a quarter of a mile, climbing one flight of stairs without resting, or performing basic activities of daily living (ADLs). Persons with plans to leave the area within 3 years; who required an assistive device, such as a cane or walker; who reported being actively treated for cancer; or who were participating in a clinical trial were excluded. Eligible participants were scheduled for a home interview during which eligibility was confirmed, consent was obtained, and a comprehensive interview was conducted followed by a clinic examination that included assessment of mobility. The protocol was approved by the institutional review boards at the 2 field centers and the coordinating center. All participants gave written informed consent.

Thelong-distancecorridorwalkwasconducted after enrollment as an objective measure of exercise capacity to complement the self-report of ability to walk a quarter of a mile, which is about 400 m. The methods for the long-distance corridor walk have been published.15-17 Briefly, participants received instructions to walk 400 m in a hallway on a 20-m per segment course for 10 laps (40 m per lap) after a 2-minute warm-up with standard encouragement given at each lap. Instructions were to walk as quickly as you can, without running, at a pace you can maintain. Participants (n=395, 12.8%) were excluded from this test for medical safety because of potentially acute electrocardiogram abnormalities, elevated blood pressure (200/110 mm Hg), resting heart rate higher than 120/min or less than 40/min, recent exacerbation of chest pain, shortness of breath, or a recent cardiac event or procedure (FIGURE 1). Of the 2680 eligible for the test, 2324 (86%) completed the full 400 m while 356 (13%) did not complete the test15 (Figure 1). Participants could stop for fatigue or symptoms. The staff stopped the test for persistent tachycardia (135/min) by heart rate monitor. Blood pressure response, heart rate response,andheartraterecovery(change from end heart rate until 2 minutes after) were also assessed.
Outcomes

Figure 1. Long-Distance Corridor Walk Exclusions

3075 Adults Aged 70-79 y Enrolled in the Health, Aging, and Body Composition Study 395 Excluded From Long-Distance Corridor Walk 173 Abnormal Vital Signs or Electrocardiogram Results 24 Recent Cardiac Symptoms or Surgery 198 Recent Chest Pain, Shortness of Breath, or Fainting 2680 Eligible for Long-Distance Corridor Walk 356 Unable to Complete 400 m 105 Unable to Walk 2 min 153 Heart Rate 135/min 82 Leg Pain 33 Chest Pain, Feel Faint, or Short of Breath 71 Other 2324 Completed 400 m

*Participants could have more than 1 reason for not completing the walk.

Surveillance was conducted by inperson examination alternating with a telephone interview every 6 months. Hospital records, death certificates, informant interviews, and autopsy data were reviewed by committee to adjudicate immediate and underlying causes of death. Incident cardiovascular disease was defined as coronary heart disease (coronary heart diseasedefinite or probable myocardial infarction, hospitalization for angina, coronary heart disease death) or stroke. Persistent mobility limitation was defined as 2 consecutive reports of having any difficulty walking a quarter of a mile or climbing stairs, or based on 1 report followed by the death of the participant prior to the

next follow-up, with a proxy report that the difficulty had been present for more than 6 months. Disability for mobility was defined as 2 consecutive reports of severe difficulty or inability to perform these tasks. Final determination of disability status was made based on interview or, if needed, proxy interview, hospital records, or both. Follow-up for all events was complete through 6 years with a mean (SD) follow-up of 4.9 years (0.9) and was 98% complete.
Long-term Health Conditions

Coronary heart disease was defined as myocardial infarction, angina, or history of coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. Cerebrovascular disease was defined as self-reported history of transient ischemic attack or stroke. Prevalent cardiovascular disease was defined as coronary heart disease or stroke. Peripheral artery disease was present if the participant reported intermittent claudication or history of bypass or angioplasty in the leg arteries. Knee pain was considered to be consistent with osteoarthritis if

2006 American Medical Association. All rights reserved.

(Reprinted with Corrections) JAMA, May 3, 2006Vol 295, No. 17 2019

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

reported to be present for at least 1 month of the past year. Depression was considered as present if the participant reported treatment for depression and used an antidepressant or if there was no self-report of treatment but antidepressant use was recorded among medications inventoried. Diabetes and hypertension were defined by selfreport, confirmed by medication use. -Blockers, digoxin, and calcium channel blockers were considered as potenTable 1. Characteristics of Study Participants*

tial confounders when heart rate response and recovery were examined. Indicators of subclinical or otherwise undiagnosed disease included ankle-brachial index,20 major electrocardiogram abnormalities (major Q or QS abnormality, major ST or T wave abnormality, ventricular conduction defects, or left ventricular hypertrophy21), forced expiratory volume in first second/forced vital capacity (FEV1/ FVC), Center for Epidemiological Stud-

ies-Depression Scale (CES-D) score,22 fasting glucose (Vitro 950 analyzer, Johnson and Johnson, Rochester, NY), and systolic blood pressure.
Other Potential Confounders

Other factors associated with 400-m walk performance that were considered as potential confounders included physical activity, body mass index, smoking, and total cholesterol level. Physical activity was determined using a standardized

Quartile of Walk Time, s Characteristics Age, mean (SD), y Sex and race, No. (%) Men Black White Women Black White Prevalent health conditions, No. (%) Coronary heart disease Peripheral arterial disease Stroke Hypertension Diabetes Pulmonary disease Knee pain Depression Risk factors, No. (%) Ankle-brachial index 0.9 Major ECG abnormalities Smoking Never Former Current Physical activity group Sedentary Active lifestyle Exerciser FEV1/FVC, mean (SD) Body mass index, mean (SD) Fasting glucose, mean (SD), mg/dL Systolic blood pressure, mean (SD), mm Hg CES-Depression scale score, mean (SD) Total cholesterol, mean (SD), mg/dL Short portable performance battery score (range, 0-12), mean (SD) Excluded (n = 395) 74.1 (2.9) 180 (45.6) 84 (46.7) 96 (53.3) 215 (54.4) 123 (57.2) 92 (42.8) 112 (29.0) 25 (6.7) 44 (11.3) 180 (45.6) 81 (20.6) 36 (9.9) 24 (6.2) 28 (7.1) 122 (30.9) 166 (42.0) 160 (40.5) 186 (47.1) 49 (12.4) 126 (31.9) 200 (50.6) 69 (17.5) 0.7 (0.1) 28.0 (5.5) 111 (46.6) 143 (28.9) 6.0 (6.7) 203 (43.0) 9.43 (2.2) Stopped (n = 356) 73.9 (2.9) 122 (34.3) 59 (48.4) 63 (51.6) 234 (65.7) 140 (59.8) 94 (40.2) 73 (21.5) 40 (11.8) 46 (13.0) 156 (43.8) 77 (21.8) 20 (6.0) 30 (8.5) 21 (5.9) 116 (32.6) 125 (35.1) 149 (42.0) 160 (45.1) 46 (13.0) 93 (26.1) 189 (53.1) 74 (20.8) 0.8 (0.1) 29.0 (5.8) 112 (42.6) 138 (20.2) 5.2 (5.8) 206 (36.6) 9.50 (2.0) 201-290 (n = 579) 72.9 (2.6) 401 (69.3) 85 (21.2) 316 (78.8) 178 (30.7) 37 (20.8) 141 (79.2) 71 (12.4) 13 (2.3) 31 (5.4) 192 (33.2) 53 (9.2) 14 (2.5) 12 (2.1) 26 (4.5) 50 (8.6) 140 (24.2) 253 (43.8) 289 (50.1) 35 (6.1) 68 (11.7) 247 (42.7) 264 (45.6) 0.8 (0.1) 25.8 (3.3) 99.8 (29.6) 133 (18.7) 3.8 (4.5) 199 (35.3) 10.85 (1.1) 290-323 (n = 579) 73.4 (2.8) 318 (54.9) 99 (31.1) 219 (68.9) 261 (45.1) 66 (25.3) 195 (74.7) 91 (16.0) 24 (4.2) 33 (5.7) 212 (36.6) 67 (11.7) 17 (3.1) 30 (5.3) 33 (5.8) 71 (12.3) 153 (26.4) 246 (42.5) 293 (50.6) 40 (6.9) 116 (20.0) 296 (51.1) 167 (28.8) 0.7 (0.1) 26.6 (3.9) 101 (25.8) 134 (18.7) 4.4 (5.1) 202 (37.7) 10.56 (1.1) 323-362 (n = 579) 73.7 (2.9) 256 (44.2) 114 (44.5) 142 (55.5) 323 (55.8) 128 (39.6) 195 (60.4) 86 (15.3) 24 (4.3) 36 (6.3) 229 (39.6) 87 (15.1) 18 (3.4) 30 (5.3) 32 (5.6) 93 (16.1) 175 (30.2) 278 (48.0) 241 (41.6) 60 (10.4) 120 (20.7) 347 (59.9) 112 (19.3) 0.7 (0.1) 27.3 (4.4) 104 (32.5) 135 (19.1) 4.6 (5.1) 204 (38.9) 10.11 (1.3) 362-942 (n = 587) 74.1 (3.0) 214 (36.5) 111 (51.9) 103 (48.1) 373 (63.5) 235 (63.0) 138 (37.0) 80 (14.0) 32 (5.6) 57 (9.9) 251 (43.8) 103 (17.6) 22 (4.1) 44 (7.6) 57 (9.7) 154 (26.2) 197 (33.6) 262 (44.8) 235 (40.2) 88 (15.0) 197 (33.6) 326 (55.5) 64 (10.9) 0.8 (0.1) 28.5 (5.6) 111 (42.6) 136 (20.4) 4.9 (5.0) 203 (40.2) 9.34 (1.6)

Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; ECG, electrocardiogram; FEV1/FVC, forced expiratory volume in first second/forced vital capacity. SI conversion factor: To convert total cholesterol from mg/dL to mmol/L, multiply by 0.0259 and glucose from mg/dL to mmol/L, multiply by 0.0555. *All comparisons across the 6 groups had P values .01, except cholesterol, which was not significant. P values are from 2 test of proportions for categorical variables and analysis of variance for comparison of mean values of continuous variables. Body mass index is calculated as weight in kilograms divided by height in meters squared.

2020

JAMA, May 3, 2006Vol 295, No. 17 (Reprinted with Corrections)

2006 American Medical Association. All rights reserved.

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

questionnaire designed specifically for the Health ABC study, modeled from commonly used leisure-time physical activity assessments including the leisuretime physical activity questionnaire.23,24 Participants who reported at least 1000 kcal/wk of formal exercise were defined as exercisers. The remainder were classified as sedentary if they reported expending no more than 2719 kcal/wk of total physical activity and were classified as having an active lifestyle if they reported expending more than 2719 kcal/wk of total physical activity.25 Body mass index was examined as a continuous variable. Smoking was classified as current, past, or never. Total serum cholesterol was measured from a fasting specimen (Vitro 950 analyzer). Lower extremity function was also assessed using the Established Populations for the Epidemiologic Studies of the Elderly short physical performance battery.26
Statistical Analyses

outcome using, first, adjusted for demographics and chronic health conditions and medications, and then for 400-m walk time. Interactions between completion group or continuous performance and race and sex were tested difference in the association of walk performance with each outcome and none were significant. Exclusion of events in the first 6 months did not change the results. All analyses were conducted using SAS statistical software, version 8.0 (SAS Institute Inc, Cary, NC). All reported P values are 2-sided; P.05 was considered statistically significant. RESULTS Participant characteristics by completion categories and quartile of performance time among completers (TABLE 1) show that those who completed the walk and those who walked faster were slightly younger; more often were men or of white race; were less likely to have prevalent health conditions, subclinical disease, or cardiovascular risk factors; had lower body mass index, calculated as weight in kilograms divided by height in meters squared; and were more physically active. After 6 years, 430 participants had died. Among those excluded from or who stopped, the crude total mortality rates were higher than for those who completed the long-distance corridor walk (TABLE 2). This difference was attenuated after adjustment for sociodemographic characteristics, long-term conditions, subclinical disease indicators, and cardiovascular disease risk factors. After adding the short physical performance battery score to the model, the HR were further attenuated but remained significantly greater than 1.00 among those who were excluded. Hazard ratios for cardiovascular and noncardiovascular mortality were similar. Incident cardiovascular disease was evaluated among the 2234 participants who did not have clinical cardiovascular disease at baseline. In each model, those who stopped or who were excluded from the long-distance corridor walk had a higher rate of incident cardiovascular disease than those

Analysis of variance for continuous variables and 2 tests for categorical variables were used to test differences in characteristics across the completion status groups and quartiles of performance. Crude outcome rates were calculated per 1000 person-years. Cox proportional hazard models were used to assess hazard ratios (HRs) for outcomes of total mortality, incident cardiovascular disease, mobility limitation, and mobility disability. The proportional hazards assumption held for all outcomes. Spline interpolation smoothing plots supported a linear relationship between walk time and outcomes. Hazard ratios were estimated for completion status groups and separately per SD of 400-m walk time (60 seconds or 1 minute). These models were adjusted for other variables found in earlier analyses15 to be associated with 400-m walk time as well as other risk factors for total cardiovascular disease. Models were subsequently adjusted for lower-extremity performance. Blood pressure response, heart rate response, and heart rate change were examined as separate independent variables in additional multivariate Cox models for each

who had completed the walk. However, after multivariable adjustment, neither exclusion from nor stopping the long-distance corridor walk were associated with incident cardiovascular disease when compared with those who completed the walk. Persistent mobility limitation occurred in 1360 (44%) of participants. Those who were excluded from or who stopped the 400-m walk had significantly higher HRs for persistent mobility limitation than did those who completed the test. These associations were only modestly attenuated with adjustment and were not explained by baseline lower extremity performance. Similar associations were found when mobility disability was considered as the outcome. Among those who completed the long-distance corridor walk (TABLE 3), each additional minute of longer performance time was related to a 35% higher risk of death after adjustment for age and sex. After further adjustment for demographics, long-term conditions, other health indicators, and the short physical performance battery score, the HR for mortality was only minimally attenuated. Hazard ratios were similar for cardiovascular and noncardiovascular mortality. The fully adjusted HR for cardiovascular mortality was 1.26 (95% confidence interval [CI], 1.00-1.58) and for noncardiovascular mortality was 1.33 (95% CI, 1.16-1.52) for each minute of walk time. This same pattern was seen when evaluating incident cardiovascular disease as the outcome. For all those who completed the long-distance corridor walk, the HR for persistent mobility limitation was higher than observed for mortality or cardiovascular disease and only modestly attenuated after multivariate adjustment, including the short physical performance battery score. Adjustment for the short 6-m gait speed in place of the full battery gave similar results. All associations were similar for mobility disability. Among participants who completed the test and after adjusting for potential confounders, those in the poorest quartile of functional capacity (walk time

2006 American Medical Association. All rights reserved.

(Reprinted with Corrections) JAMA, May 3, 2006Vol 295, No. 17 2021

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

362 seconds) had a higher risk of death than those in the best quartile (walk time 290 seconds; crude event rate, 14.2 vs 39.9 per 1000 person-years; adjusted HR, 3.23; 95% CI, 2.11-4.94; P.001). Similarly, they had a higher risk of incident cardiovascular disease (27.7 vs 36.0 per 1000 person-years; adjusted HR, 1.61; 95% CI, 1.05-2.45; P.03), mobility limitation (27.3 vs 180.0 per 1000 person-years; adjusted HR, 4.43; 95% CI, 3.39-5.78; P.001), and mobility disability (9.6 vs 60.2 per 1000 person years; adjusted HR, 4.43; 95% CI, 2.88-6.82; P.001).

FIGURE 2 and FIGURE 3 show survival curves for each outcome in men and in women. In these analyses, the groups that stopped or were excluded were examined along with the 4 quartiles of walk time. For each outcome, event rates were similar for those stopping the test or excluded from the test and generally were progressively lower for each quartile of better performance. There were no significant differences in risk between men and women, but the associations with incident cardiovascular disease were not significant in women.

Finally, we assessed the role of the cardiovascular response to the longdistance corridor walk in predicting these outcomes (TABLE 4). Higher heart rate response and faster heart rate recovery were both inversely associated with mortality, incident cardiovascular disease, persistent mobility limitation, and mobility disability, but these associations were largely explained by health conditions and faster longdistance corridor walk times. Blood pressure response was not associated with any of these outcomes. Additional analysis for threshold effects us-

Table 2. Event Rates and Hazard Ratios for Total Mortality, Incident Cardiovascular Disease, Mobility Limitation, and Mobility Disability by Completion Status of Long-distance Corridor Walk
Hazard Ratio (95% Confidence Interval) No. of Participants 3075 395 356 2324 2234 228 239 1767 3075 395 356 2324 3075 395 356 2324 No. of Events 79 67 284 51 49 259 244 232 884 139 134 375 Events per 1000 Person-Years 41.8 39.8 24.7 49.9 45.1 30.8 181.7 212.6 79.1 75.7 85.2 28.8 Age- and Sex-Adjusted 1.74 (1.35-2.23) 1.79 (1.36-2.34) 1.00 1.78 (1.32-2.41) 1.54 (1.13-2.11) 1.00 2.16 (1.87-2.49) 2.50 (2.16-2.89) 1.00 2.54 (2.08-3.09) 2.85 (2.33-3.48) 1.00 Multivariate Adjustment* 1.43 (1.05-1.96) 1.25 (0.89-1.77) 1.00 1.29 (0.87-1.92) 1.25 (0.80-1.94) 1.00 1.56 (1.34-1.83) 2.01 (1.72-2.36) 1.00 1.81 (1.46-2.25) 2.14 (1.72-2.66) 1.00 Further Adjusted for Lower Extremity Function 1.38 (1.00-1.90) 1.17 (0.83-1.68) 1.00 1.29 (0.88-1.92) 1.20 (0.82-1.76) 1.00 1.52 (1.30-1.78) 1.86 (1.58-2.18) 1.00 1.64 (1.32-2.05) 1.95 (1.56-2.44) 1.00

Mortality Excluded Stopped Completed Incident CVD Excluded Stopped Completed Mobility limitation Excluded Stopped Completed Mobility disability Excluded Stopped Completed

Abbreviation: CVD, cardiovascular disease. *Adjusted for age, sex, race, smoking history, pack-years of smoking, systolic blood pressure, total cholesterol, fasting glucose, body mass index, physical activity, coronary heart disease, intermittent claudication, stroke, depression symptoms, ankle-brachial index, major electrocardiogram abnormalities, and forced expiratory volume in first second/ forced vital capacity. Adjusted for lower extremity function assessed using short portable performance battery.

Table 3. Event Rates and Hazard Ratios for Total Mortality, Incident Cardiovascular Disease, Mobility Limitation, and Mobility Disability for Those Who Completed the 400-m Walk
Hazard Ratio (95% Confidence Interval)* Events Mortality Incident CVD Mobility limitation Mobility disability No. of Participants 2324 1767 2324 2324 No. of Events 284 259 884 375 Events per 1000 Person-Years 24.7 30.8 79.1 28.8 Age- and Sex-Adjusted 1.35 (1.24-1.47) 1.25 (1.10-1.41) 1.70 (1.62-1.78) 1.66 (1.55-1.78) Multivariate Adjustment 1.29 (1.15-1.46) 1.14 (0.97-1.33) 1.59 (1.50-1.69) 1.59 (1.46-1.73) Further Adjusted for Lower Extremity Function 1.29 (1.12-1.48) 1.20 (1.01-1.42) 1.52 (1.41-1.63) 1.52 (1.37-1.70)

Abbreviation: CVD, cardiovascular disease *Hazard ratios are reported per standard deviation of performance time (1 minute). Adjusted for age, sex, race, smoking history, pack-years of smoking, systolic blood pressure, total cholesterol, fasting glucose, body mass index, physical activity, coronary heart disease, intermittent claudication, stroke, depression symptoms, ankle-brachial index, major electrocardiogram abnormalities, and forced expiratory volume in first second/ forced vital capacity. Adjusted for lower extremity function assessed using short portable performance battery.

2022

JAMA, May 3, 2006Vol 295, No. 17 (Reprinted with Corrections)

2006 American Medical Association. All rights reserved.

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

ing quartiles of blood pressure and heart rate change did not show any evidence of a threshold effect in these associations. COMMENT In a large cohort of well-functioning community-based older adults, inability to complete or exclusion from walking 400 m was associated with a higher risk of mortality, incident cardiovas-

cular disease, and mobility limitation and mobility disability. Among those able to complete a 400-m course, each minute of performance time was associated with a 29% higher rate of mortality, 20% higher rate of cardiovascular disease, and 52% higher rates of mobility limitation and disability. Baseline health status and other tests of function were consistent in both men and women and blacks and whites. These

findings reflect the well-established evidence in middle-aged men and women adults that fitness is an independent predictor of cardiovascular and total mortality.1-3 Tests, such as the long-distance corridor walk, were initially developed to evaluate capacity in patients who were unable to complete traditional treadmill test protocols, such as patients with advanced chronic obstructive pulmo-

Figure 2. Kaplan-Meier Plots of Mortality and Incident Cardiovascular Disease Event Rates
Men
70 60 50 Excluded Stopped Quartile 1 Quartile 2 Quartile 3 Quartile 4

Mortality
70 60 50

Women

Mortality, %

40 30 20 10 0 0 0.5

Mortality, %

40 30 20 10 0

P <.001

P <.001

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

Years
No. at Risk Excluded Stopped Quartile 1 Quartile 2 Quartile 3 Quartile 4 180 122 401 318 254 211 175 119 401 312 253 206 169 113 393 303 248 193 159 109 386 293 237 178 152 102 377 283 226 167 70 55 206 152 126 88 215 234 178 260 323 369 213 228 178 260 321 365 210 217 178 259 318 356

Years
203 211 175 254 313 346 198 208 172 251 309 335 88 117 124 154 179 184

Incident Cardiovascular Disease Men

70 70

Women Incident Cardiovascular Disease, %

Incident Cardiovascular Disease, %

60 50 40 30 20 10 0 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5

60 50 40 30 20 P = .16 10 0 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5

P <.001

Years
No. at Risk Excluded Stopped Quartile 1 Quartile 2 Quartile 3 Quartile 4 96 67 304 219 174 142 91 62 298 212 170 132 88 55 285 202 159 123 78 52 275 194 148 109 72 49 263 182 137 102 31 26 136 97 72 48 132 172 155 223 269 281 125 165 152 218 267 275 120 158 151 216 259 268

Years
116 150 146 206 250 255 113 144 141 202 242 246 49 82 104 125 137 139

Rates are according to quartile of long-distance corridor walk and completion status groups in men and women for mortality and cardiovascular disease. The P values are based on the log-rank test.

2006 American Medical Association. All rights reserved.

(Reprinted with Corrections) JAMA, May 3, 2006Vol 295, No. 17 2023

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

nary disease27 or heart failure.18 These patients and many older adults are unable to walk at the usual starting pace for many treadmill protocols of at least 3.0 mph or 1.34 m/s. In the Health ABC cohort, only 31% of those who completed the 400-m distance walked at this pace or faster and most performed below the pace of the group in the validation study.17 Nevertheless, our findings support the potential for this test

to be a useful substitute for treadmill testing as a predictor of adverse outcomes in older adults. Because the long-distance corridor walk was previously shown to be a good summary measure of multiple longterm health conditions in the Health ABC cohort,15 we had hypothesized that its ability to predict poor outcomes might be largely explained when these conditions were considered in the mod-

els. We adjusted for all of the chronic health conditions associated with the long-distance corridor walk at baseline as well as measures of the extent of longterm disease using noninvasive tests and for cardiovascular risk factors. After adjustment for these factors and after administering a brief lower-extremity performance battery, the long-distance corridor walk performance time remained an independent predictor of

Figure 3. Kaplan-Meier Plots of Mobility Limitation and Disability Event Rates

Excluded Stopped Quartile 1 Quartile 2 Quartile 3 Quartile 4 P <.001

Men

Mobility Limitation
70 60

Women

70 60

Mobility Limitation, %

50 40 30 20 10 0 0 0.5

Mobility Limitation, %

50 40 30 20 10 0

P <.001

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

Years
No. at Risk Excluded Stopped Quartile 1 Quartile 2 Quartile 3 Quartile 4 180 122 398 318 255 207 138 81 393 300 230 168 117 67 378 277 210 127 96 60 362 262 183 99 82 52 345 239 157 82 68 46 333 219 137 69 213 233 178 261 322 368 152 145 176 253 288 292 121 109 168 238 264 239

Years
102 94 164 225 234 200 88 80 156 214 212 171 68 69 152 201 188 137

Mobility Disability Men

70 60 70 60

Women

Mobility Disability, %

50 40 30 20 10 0 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 P <.001

Mobility Disability, %

50 40 30 20 10 0 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 P <.001

Years
No. at Risk Excluded Stopped Quartile 1 Quartile 2 Quartile 3 Quartile 4 180 122 400 318 254 209 164 106 400 310 250 199 150 93 390 300 238 175 131 87 380 289 222 152 118 79 369 274 203 138 104 67 355 256 185 118 233 213 178 261 321 367 198 191 177 260 317 340 171 171 177 256 307 319

Years
155 151 173 246 290 299 142 143 170 239 278 270 121 124 168 232 258 243

Rates are according to quartile of long-distance corridor walk and completion status groups in men and women for mobility limitation and mobility disability. The P values are based on the log-rank test. 2024 JAMA, May 3, 2006Vol 295, No. 17 (Reprinted with Corrections)

2006 American Medical Association. All rights reserved.

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

mortality, cardiovascular disease, mobility limitation, and disability. To the extent that the long-distance corridor walk assesses fitness or exercise capacity, it suggests that fitness is itself a prognostic factor for these adverse health outcomes in persons in their eighth decade of life and further supports the potential that exercise capacity is a potential target as a modifiable risk factor even in those aged 70 years and older. Alternatively, this test may capture additional information about the severity of underlying long-term conditions not captured by our measures of clinical and subclinical disease. Heart rate recovery after exercise is a manifestation of reactivated vagal tone that occurs normally after exercise.28 Others have found it to be an independent predictor of mortality after accounting for functional capacity.5-8 Vagal tone appears to protect against fatal arrhythmias.29 In our study, heart rate recovery was not independent of other measures of functional capacity, most likely because our test was self-paced rather than maximal or submaximal. Although the association of heart rate recovery was not independent of the 400-m walk performance time in the Health ABC cohort, it might be a more easily accessible prognostic indicator in clinical settings than walk-time per se. The protocol for the test was designed to encourage a good effort, but at a pace that could be maintained for 10 laps, thus there was no ramping up of the speed or slope as is done with submaximal, symptom-limited or maximal treadmill tests. Such self-paced tests have proven to be very safe when appropriate exclusions are applied.30 For individuals who are unable to walk 400 m or who would be excluded for safety reasons, a short-course gait speed or short lower-extremity performance battery still provides important prognostic information.26 The longer walk may be most useful for those who appear to be well functioning using the shorter tests.31 Poor lower-extremity performance is strongly predictive of future disability, hospitalization, and mortality.26

Table 4. Cardiovascular Response to the 400-m Component of the Long-Distance Corridor Walk
Hazard Ratio (95% Confidence Interval) No. of Participants Mortality Blood pressure response Heart rate response Heart rate recovery Incident CVD Blood pressure response Heart rate response Heart rate recovery Mobility limitation Blood pressure response Heart rate response Heart rate recovery Mobility disability Blood pressure response Heart rate response Heart rate recovery 2324 1.08 (0.99-1.18) 0.94 (0.90-0.97) 0.87 (0.81-0.94) 2324 1.21 (1.04-1.40) 0.89 (0.80-0.995) 0.86 (0.76-0.97) 1.12 (0.96-1.31) 0.92 (0.82-1.02) 0.86 (0.76-0.99) 0.88 (0.80-0.97) 0.89 (0.82-0.96) 1.07 (0.93-1.22) 1.00 (0.92-1.10) 2324 0.94 (0.82-1.08) 0.92 (0.87-0.98) 0.83 (0.74-0.93) 1767 1.13 (0.97-1.31) 0.92 (0.81-1.04) 0.85 (0.74-0.99) 0.89 (0.76-1.05) 0.92 (0.77-1.11) Age- and Sex-Adjusted Multivariate Adjustment* Further Adjusted for 400-m Walk Time

0.97 (0.84-1.13)

Abbreviation: CVD, cardiovascular disease; empty cells indicate that simple models did not find a significant effect. *Adjusted for age, sex, race, smoking history, pack-years of smoking, systolic blood pressure, total cholesterol, fasting glucose, body mass index, physical activity, coronary heart disease, intermittent claudication, stroke, depression symptoms, ankle brachial index, major electrocardiogram abnormalities, forced expiratory volume in first second/forced vital capacity, and use of digoxin, -blockers, or calcium channel blockers. Hazard ratios are reported per SD of blood pressure response equal to 19.5 mm Hg. Hazard ratios are reported per SD of heart rate response equal to 19.4/min. Hazard ratios are reported per SD of heart rate recovery equal to 11.0/min.

Gait speed and lower-extremity performance batteries capture many aspects of age-related chronic conditions and overall functional status, but these measures tend to have ceiling effects, limiting discrimination among healthier older adults.30 A 400-m longdistance corridor walk can discriminate levels of function of those with normal performance on a lowerextremity battery.32 Short walks do not adequately assess into aerobic fitness,33 although the best time or length for extended protocols to capture fitness needed is still debated. There are several important limitations to consider. The Health ABC cohort was selected to be free of disability and mobility impairment by self- report, thus interpretations of these findings are limited to these communitydwelling older adults. The outcomes of mobility limitation and disability were based on self-report. Future studies should assess prediction of other performance-based functional outcomes.

This study demonstrates that the ability to walk 400 m and timed performance discriminate mortality and cardiovascular risk and risk for mobility limitation and disability in communitydwelling older adults without known difficulty performing mobility-related tasks. These findings provide validation of the importance of having the capacity to walk longer distances and show that there is a wide range of function and risk in apparently wellfunctioning older adults. This test may be useful in clinical practice for the identification of early decline in function.
Author Affiliations: Departments of Epidemiology and Medicine (Drs Newman and Boudreau and Ms Naydeck), Physical Therapy (Dr Brach) and Geriatric Medicine (Dr Studenski), University of Pittsburgh, Pittsburgh, Pa; Intramural Research Program, National Institute on Aging, Baltimore, Md (Dr Simonsick); Division of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC (Dr Kritchevsky); Department of Epidemiology and Biostatistics, University of California San Francisco (Dr Nevitt); Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville (Dr Pahor); Department of Preventive Medicine, University of Tennessee, Memphis (Dr Satterfield); and Laboratory of Epidemiology,

2006 American Medical Association. All rights reserved.

(Reprinted with Corrections) JAMA, May 3, 2006Vol 295, No. 17 2025

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012

WALK PERFORMANCE AND MORTALITY AND CVD

Demography and Biometry, National Institute on Aging, Bethesda, Md (Dr Harris). Author Contributions: Drs Newman and Boudreau and Ms Naydeck had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Newman, Simonsick, Kritchevsky, Nevitt, Pahor, Studenski. Acquisition of data: Newman, Simonsick, Naydeck, Kritchevsky, Nevitt, Pahor, Satterfield, Harris. Analysis and interpretation of data: Newman, Simonsick, Naydeck, Boudreau, Kritchevsky, Nevitt, Pahor, Brach, Studenski. REFERENCES 1. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 2005;353:468-475. 2. Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the Lipid Research Clinics Prevalence Study. JAMA. 2003; 290:1600-1607. 3. Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and allcause mortality: a prospective study of healthy men and women. JAMA. 1989;262:2395-2401. 4. Myers J, Prakash M, Froelicher V, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346: 793-801. 5. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol. 2003;42: 831-838. 6. Gibbons RJ. Abnormal heart-rate recovery after exercise. Lancet. 2002;359:1536-1537. 7. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999; 341:1351-1357. 8. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med. 2000;132:552-555. 9. Swerts PMJ, Mostert R, Wouters EFM. Comparison of corridor and treadmill walking in patients with severe chronic obstructive pulmonary disease. Phys Ther. 1990;70:439-442. 10. Lucas C, Stevenson LW, Johnson W, et al. The 6-minute walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. Am Heart J. 1999;138:618-624. 11. Butland RJA, Pang J, Gross ER, et al. Two-, six-, and 12-minute walking tests in respiratory disease. BMJ. 1982;284:1607-1608. 12. Peloquin L, Gauthier P, Bravo G, et al. Reliability and validity of the five-minute walking field test for estimating VO2 peak in elderly subjects with knee osteoarthritis. J Aging Phys Act. 1998;6:36-44. 13. Simonsick EM, Montgomery PS, Newman AB, et al. Measuring fitness in healthy older adults: the Health ABC long-distance corridor walk. J Am Geriatr Soc. 2001;49:1544-1548. 14. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA. 1993;270:1702-1707. 15. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: a quick measure of functional status in elderly adults. Chest. 2003;123:387-398. 16. Newman AB, Haggerty CL, Kritchevsky SB, Nevitt MC, Simonsick EM; Health ABC Collaborative Research Group. Walking performance and cardiovascular response: associations with age and morbidity. J Gerontol A Biol Sci Med Sci. 2003;58A:715-720. 17. Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in well functioning older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc. 2006;54:127-132. 18. Peeters P, Mets T. The 6-minute walk as an appropriate exercise test in elderly patients with chronic heart failure. J Gerontol A Biol Sci Med Sci. 1996;51: M147-M151. 19. Pober DM, Freedson PS, Kline GM, et al. Development and validation of a one mile treadmill walk test to predict peak oxygen uptake in healthy adults ages 40 to 79 years. Can J Appl Physiol. 2002;27:575588. 20. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88:837845. 21. Furberg CD, Manolio TA, Psaty BM, et al. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol. 1992;69:1329-1335. 22. Penninx BWJH, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition Study. Biol Psychiatry. 2003;54:566-572. 23. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure-time physical activities. J Chronic Dis. 1978;31:741-755. 24. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25:71-83. 25. Brach JS, Simonsick EM, Kritchevsky S, Yaffe K, Newman AB; Healthy, Aging and Body Composition Study Research Group. The associations between physical function and lifestyle activity and exercise in the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2004;52:502-509. 26. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556-561. 27. McGavin CR, Artvinli M, Naoe H, et al. Dyspnea, disability and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ. 1978;2:241-243. 28. Imai K, Sato H, Hori M, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol. 1994;24:1529-1535. 29. Schwartz PJ. The autonomic nervous system and sudden death. Eur Heart J. 1998;19:F72-F80. 30. Simonsick EM, Newman AB, Nevitt MC, et al. Measuring higher level physical function in wellfunctioning older adults: expanding familiar approaches in the Health ABC study. J Gerontol A Biol Sci Med Sci. 2001;56:M644-M649. 31. Sayers SP, Newman AB, Guralnik JM, Brach J, Fielding RA. Concordance and discordance between two measures of lower extremity function: 400 meter self paced walk and SPPB. Aging Clin Exp Res. In press. 32. Sayers SP, Brach JS, Newman AB, Heeren TC, Guralnik JM, Fielding RA. Use of self-report to predict ability to walk 400 meters in mobility-limited older adults. J Am Geriatr Soc. 2004;52:2099-2103. 33. Simonsick EM, Gardner AW, Poehlman ET. Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures. Aging (Milano). 2000;12:274-280. Drafting of the manuscript: Newman, Naydeck, Nevitt. Critical revision of the manuscript for important intellectual content: Newman, Simonsick, Naydeck, Boudreau, Kritchevsky, Nevitt, Pahor, Satterfield, Brach, Studenski, Harris. Statistical analysis: Newman, Simonsick, Naydeck, Boudreau. Obtained funding: Newman, Kritchevsky, Nevitt, Harris. Administrative, technical, or material support: Newman, Simonsick, Naydeck, Pahor, Satterfield, Harris. Study supervision: Kritchevsky. Financial Disclosures: None reported. Funding/Support: This study was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging (NIA), and contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. Role of the Sponsor: This study was funded by contracts from the NIA. The NIA scientists had substantial involvement in the study design, data collection, analysis, interpretation, and manuscript preparation. Acknowledgment: We thank Michelle E. Utz-Kiley, research assistant, University of Pittsburgh, Department of Epidemiology, for her assistance with manuscript preparation.

2026

JAMA, May 3, 2006Vol 295, No. 17 (Reprinted with Corrections)

2006 American Medical Association. All rights reserved.

Downloaded From: http://jama.jamanetwork.com/ by a Universidade Catlica de Braslia User on 08/20/2012